Adel Kardosh

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid–based proteasome inhibitors

Encouse B. Golden, Philip Y. Lam, Adel Kardosh et al. · Blood · 2009 · 287 citations

Medicine, Oncology, Pharmacology +15

HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death by Triggering Endoplasmic Reticulum Stress

Peter Pyrko, Adel Kardosh, Weijun Wang et al. · Cancer Research · 2007 · 140 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib

Adel Kardosh, Encouse B. Golden, Peter Pyrko et al. · Cancer Research · 2008 · 136 citations

Medicine, Oncology, Pharmacology +14